Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Nexium NDA Includes "On-Demand" Dosing

Executive Summary

AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.

You may also be interested in...



AstraZeneca Nexium Labeling In Sweden Cites 93% GERD Healing At 8 Weeks

AstraZeneca's proton pump inhibitor Nexium demonstrates a 93% healing rate in erosive reflux esophagitis, according to Swedish labeling for the drug.

AstraZeneca Nexium Labeling In Sweden Cites 93% GERD Healing At 8 Weeks

AstraZeneca's proton pump inhibitor Nexium demonstrates a 93% healing rate in erosive reflux esophagitis, according to Swedish labeling for the drug.

AstraZeneca Emphasizes Size As Key To Growth In Rx Market

AstraZeneca is guiding investors in the pharmaceutical industry to consider size - both in terms of corporate resources and individual products - as the key to growth.

Related Content

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel